Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYDE-HCM Trial
2024-520086-31-00Phase 4Authorised
- Sponsor
- Medical University of Graz
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of hydrochlorothiazide and valsartan in hypertrophic cardiomyopathy (HCM) and hypertension (HTN) (2 arms), sponsored by Medical University of Graz. Primary endpoint: Change in peak LVOT gradient at rest. Planned start Dec 2025; status: authorised.
02
Drugs
hydrochlorothiazidevalsartan
03
Conditions
hypertrophic cardiomyopathy (HCM)hypertension (HTN)
Beyond the preview
Go deeper on 2024-520086-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520086-31-00.